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Abstract: We describe the clinical and pathologic findings of a
68-year-old smoker with previous asbestos exposure who presented
with spontaneous hydropneumothorax and was diagnosed with syn-
chronous undifferentiated lung carcinoma and incidental malignant
pleural mesothelioma. The synchronous occurrence of these two
neoplasms is an extremely rare event with fewer than 20 reported
cases in the English literature. The accurate diagnosis of synchro-
nous tumors can be extremely challenging and the identification of
a concomitant mesothelioma in our case was not made until an
extensive immunohistochemical analysis was done on the resection
specimen. Spontaneous pneumothorax occurs much more com-
monly in patients with malignant mesothelioma than with primary
lung carcinomas. Consequently, although synchronous pleural me-
sotheliomas and lung carcinomas are infrequent, this diagnosis
should be considered when a patient with a lung mass and a history
of asbestos exposure presents with spontaneous pneumothorax and
pleural thickening on imaging. Identification of synchronous tumors
is of critical importance for determining the patient’s stage and
management and can have significant medicolegal implications
should the patient seek compensation.
Key Words:Mesothelioma, Asbestos, Pneumothorax, Lung carcinoma.
(J Thorac Oncol. 2009;4: 770–772)
CLINICAL SUMMARY
A 68-year-old male former electrician with a 40-pack
year smoking history presented with a 2-month history of
shortness of breath and fatigue. Thoracic computed tomog-
raphy demonstrated an 11.5  8.0 cm heterogeneous mass
involving the posterior segment of the right upper lobe with
an associated large hydropneumothorax (Figure 1). The mass
occluded the segmental bronchus of the right upper lobe and
crossed the oblique fissure to involve the superior segment of
the right lower lobe. A fine-needle aspiration biopsy was
positive for a nonsmall cell carcinoma with extensive necro-
sis. There was also associated mild visceral pleural thicken-
ing interpreted as possible metastatic spread of the lung
carcinoma. Enlarged mediastinal lymph nodes were not iden-
tified. Bone scan and computed tomography scans of the head
and abdomen showed no metastasis. Pleural cytology was
positive for nonsmall cell carcinoma, making it a stage IIIB
lung carcinoma. However, because of a bronchopleural fistula
with persistent air leak that precluded chemoradiation ther-
apy, a palliative pneumonectomy was planned. Finally, an
extrapleural pneumonectomy was performed because of ex-
tensive pleural disease detected intraoperatively.
Gross examination demonstrated diffuse mild nodular
thickening of the parietal pleura and a well-circumscribed
lesion measuring 12.0  8.3  7.8 cm almost completely
replacing the right upper lobe parenchyma with minimal
extension into the right lower lobe. Approximately 90% of
the lung mass was necrotic. The parietal pleura was also
resected and there was focal pleural adhesion at the site of the
tumor. The nonneoplastic lung parenchyma demonstrated
anthracosis and emphysematous changes.
Histologic examination of the parenchymal mass
showed morphologic features of an undifferentiated carci-
noma, composed of large polygonal cells containing mark-
edly pleomorphic hyperchromatic nuclei, prominent nucle-
oli, and abundant pale cytoplasm. Extensive necrosis and
numerous mitotic figures were also present (Figure 2).
There was no evidence of squamous or glandular differ-
entiation and no mucin production. The tumor focally
involved the visceral pleura at the above described site of
adhesion. In addition, both the visceral and parietal pleura
showed an epithelioid malignant mesothelioma with focal
sarcomatoid morphology. There were microscopic foci of
invasion into the lung parenchyma and into the subme-
sothelial parietal adipose tissue (Figure 3). The two tumors
collided at the site of pleural adhesion. The nonneoplastic
parenchyma showed no evidence of asbestosis and no
ferruginous bodies were identified.
The immunohistochemical studies confirmed syn-
chronous malignant pleural mesothelioma and large cell
undifferentiated lung carcinoma (Table 1). The pleural
tumor diffusely expressed the mesothelial markers. The
large cell undifferentiated carcinoma expressed epithelial
antigens with ambiguous results for specific histologic
subtype markers. Many undifferentiated epithelial cells
coexpressed thyroid transcription factor-1 and p63 protein,
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usually present in lung adenocarcinoma and squamous cell
carcinoma, respectively.
DISCUSSION
In this case study, we have presented the occurrence of
synchronous undifferentiated large cell lung carcinoma and
biphasic malignant pleural mesothelioma in a 68-year-old
male smoker with an occupational history of asbestos expo-
sure. The synchronous occurrence of these two neoplasms is
extremely uncommon, with fewer than 20 cases reported in
the English literature.1–7 It is well recognized that asbestos
is a risk factor for both malignant mesothelioma and lung
carcinoma. It has been speculated that the pathogenic
mechanisms by which asbestos induces the two malignan-
cies must be different because of the rarity of synchronous
presentation.2
The detection of synchronous malignant pleural me-
sothelioma and pulmonary carcinoma is challenging be-
cause of its seldom occurrence and the confounding radio-
logic and morphologic features. In our case, radiographic
imaging demonstrated thickening of the pleura that was
interpreted as metastatic spread of an obvious nonsmall
cell lung carcinoma. Similarly, the cytologic examination
of the pleural effusion was reported as necrosis and ma-
lignant cells consistent with the already diagnosed non-
small cell lung carcinoma. The identification of malignant
pleural mesothelioma was made only on the resection
specimen and after a thorough immunohistochemical study.
FIGURE 1. A, Axial computed tomography (CT) image
through the upper lobes demonstrates a large mass in the
right upper lobe (black arrows) obliterating the posterior
segmental bronchus of the right upper lobe. There is a large
right hydropneumothorax. Note the smooth visceral pleural
thickening (white arrows) suggestive of visceral pleural tu-
mor seeding. B, Coronal reformatted CT image obtained
with contrast demonstrates the large right upper lobe tumor
(white arrows) and the large right pleural effusion. No pari-
etal pleural thickening or nodularity is identified.
FIGURE 2. Histologic features of the undifferentiated carci-
noma demonstrating large pleomorphic cells (arrows) and
an atypical mitosis (arrowhead) (hematoxylin and eosin,
200).
FIGURE 3. Epithelioid malignant mesothelioma invading
into the submesothelial parietal adipose tissue (hematoxylin
and eosin, 200).
TABLE 1. Results of the Immunohistochemical Reactions
are Shown for the Two Neoplasms
Malignant
Mesothelioma
Undifferentiated
Carcinoma
Mesothelial markers
Calretinin  
CK5/6   (focal)
WT1  
Epithelial markers
MOC-31  
Ber-EP4   (focal)
B72.3   (focal)
mCEA   (focal)
CD15  Inconclusive
Other markers
TTF-1  
p63  
The mesothelial, epithelial, and other antibodies are separated into different groups.
CK5/6, cytokeratins 5 and 6; WT1, wilms tumor 1; mCEA, monoclonal carcino-
embryonic antigen; CD, cluster of differentiation; TTF-1, thyroid transcription factor-1.
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Interestingly, none of the reported cases in the literature of
synchronous malignant neoplasms were diagnosed before
resection or autopsy. Eleven cases were diagnosed at post-
mortem examination1,3,5,7 and seven incidental tumors were
identified after resection for lung cancer and/or malignant
pleural mesothelioma.2,4,6 It is clear that the existence of one
neoplasm can obscure the existence of a second malignancy
and can pose an extremely difficult diagnostic challenge.
In this case, the histologic dilemma was the confirma-
tion of two different tumors versus a single advanced tumor,
either mesothelioma or carcinoma, with local spreading into
adjacent structures. No single marker can be used to reliably
distinguish an epithelioid malignant mesothelioma from an
adenocarcinoma, and a comprehensive immunohistochemical
panel is mandatory to confirm the diagnosis. In our case, the
pleural lesion expressed the positive “Mesothelial Markers”
and was negative for “Epithelial Markers.”8 The opposite was
observed in the parenchymal lesion (Table 1). Although a
reduced panel can be used in the appropriate clinical setting,
when facing a differential diagnosis of an extremely infre-
quent synchronous neoplasm and a much more common
carcinoma with pleural spread, an extensive immunohisto-
chemical analysis should be performed.
A primary lung cancer resulting in spontaneous pneu-
mothorax is an extremely rare event that is responsible for
only 0.03 to 0.05% of all pneumothoraces.9 However, malig-
nant pleural mesotheliomas are associated with a pneumotho-
rax 10% of the time.10 This data suggest that in a case of
primary lung carcinoma associated with pleural thickening
and spontaneous pneumothorax, the possibility of a synchro-
nous malignant mesothelioma should be ruled out. However,
to our knowledge, this is the only case where a synchronous
mesothelioma and lung carcinoma presented as a spontaneous
hydropneumothorax.
The majority of the literature regarding synchronous
malignant neoplasms emphasizes the medicolegal aspects of
an asbestos-induced mesothelioma. Compensation is assessed
according to morbidity, estimates of salary loss, and reduc-
tion of life expectancy. The presence of a second malignancy
is taken into consideration when this calculation is per-
formed. Should the second malignancy also be asbestos
related, further compensation could be obtained.5 It is our
view that arriving at an accurate and correct diagnosis of this
rare entity is the critical step that must be achieved before
pursuing a medicolegal inquisition.
CONCLUSIONS
It is clear that the accurate diagnosis of synchronous
malignant pleural mesothelioma and primary lung carcinoma
can be extremely challenging, with one tumor obscuring the
identification of the other. In our report, cytology and thoracic
imaging identified the primary lung carcinoma but were
unable to detect the pleural malignant mesothelioma. The
presence of mesothelioma was not detected until a complete
histologic examination was performed on the resection spec-
imen and then confirmed using immunohistochemical stains.
Interestingly, the patient presented with spontaneous hydro-
pneumothorax, a rare event that occurs relatively more fre-
quently with malignant pleural mesothelioma than with a
primary lung carcinoma. Although synchronous pleural me-
sotheliomas and lung carcinomas are infrequent, this diagno-
sis should be considered when a patient with a lung mass and
a history of asbestos exposure presents with spontaneous
pneumothorax and pleural thickening on imaging. More im-
portantly, not only is the establishment of synchronous me-
sothelioma and lung carcinoma diagnosis critical for deter-
mining the stage and management, but it is also of paramount
importance for medicolegal reasons.
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